Ganaxolone

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期五, 八月 6, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Epilepsy, Company, Cyprus Securities and Exchange Commission, Private Securities Litigation Reform Act, Brain, CDKL5, Security (finance), Board, Medication, Common stock, GABAA, Employment, Adult, Ganaxolone, Therapy, Financial compensation, Forward-looking statement, Pharmaceutical industry

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees.
  • The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 45,625 shares of its common stock (the Common Stock) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

Retrieved on: 
星期二, 八月 3, 2021
Biotechnology, Pharmaceutical, Health, Chemical compounds, Anticonvulsants, GABAA receptor positive allosteric modulators, Ketones, Pregnanes, Sterols, Spacecraft, Ganaxolone, Spaceflight, Seizure, Maa, Orion, Ganaxolone, Marinus Pharmaceuticals, Orion Corporation, GANAXOLONE, MARINUS PHARMACEUTICALS, ORION CORPORATION

This collaboration not only serves as an important step in our global development strategy for ganaxolone, it also represents the confidence Orion has in its potential.

Key Points: 
  • This collaboration not only serves as an important step in our global development strategy for ganaxolone, it also represents the confidence Orion has in its potential.
  • Satu Ahomki, Senior Vice President, Commercial Operations of Orion Corporation said, We are pleased to be the partner of choice for Marinus in Europe.
  • What we have seen so far with ganaxolone is encouraging and signifies an ongoing commitment to the rare epilepsy communities.
  • Marinus expects to file a European marketing authorization application (MAA) for ganaxolone for the treatment of seizures associated with CDD by the end of Q3 2021.

Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update

Retrieved on: 
星期二, 八月 3, 2021
Biotechnology, FDA, Pharmaceutical, Health, Chemical compounds, Anticonvulsants, GABAA receptor positive allosteric modulators, Orphan drugs, Ganaxolone, Pregnanes, Sedatives, Health care, Health, CDKL5 Deficiency Disorder, Ganaxolone, Marinus Pharmaceuticals, CDKL5 DEFICIENCY DISORDER, GANAXOLONE, MARINUS PHARMACEUTICALS

We look forward to working with the FDA in their review process and remain focused on preparing for the anticipated U.S. launch.

Key Points: 
  • We look forward to working with the FDA in their review process and remain focused on preparing for the anticipated U.S. launch.
  • Ganaxolone was generally well-tolerated with a safety profile consistent with previous clinical trials, with the most frequent adverse event being somnolence.
  • Marinus received Rare Pediatric Disease (RPD) Designation from the FDA for ganaxolone for the treatment of seizures associated with CDD in July 2020.
  • Further details are available in Marinus press release distributed August 3, 2021 (Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone).

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

Retrieved on: 
星期二, 八月 3, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Managed care, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Chemical compounds, Health sciences, Ketones, Pregnanes, Sterols, CDKL5 deficiency disorder, Ganaxolone, CDKL5, Allosteric modulator

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Key Points: 
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year and is conducting a Phase 2 trial in tuberous sclerosis complex and a Phase 3 trial in refractory status epilepticus.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
星期五, 六月 11, 2021
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Chemical compounds, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Ketones, Pregnanes, Sterols, Organic compounds, Ganaxolone, Allosteric modulator, Antidepressant

Vice President, Clinical Development

Key Points: 
  • Vice President, Clinical Development
    Speakers: Scott Braunstein, M.D., Chief Executive Officer and Joe Hulihan, M.D., Chief Medical Officer
    All of the above public webcasts may be accessed through the Events & Presentations page of the Investors & Media section of the Marinus website, www.marinuspharma.com .
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call

Retrieved on: 
星期四, 五月 13, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Neurochemistry, Ketones, Sedatives, Anticonvulsants, Chloroarenes, Ganaxolone, Antidepressant, Allosteric modulator, Ketamine

b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021

Retrieved on: 
星期五, 五月 7, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Neurochemistry, Ketones, Sedatives, Anticonvulsants, Chloroarenes, Ganaxolone, Antidepressant, Allosteric modulator, Ketamine

b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
星期三, 四月 28, 2021
Biotechnology, Pharmaceutical, Health, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Ketones, Neurochemistry, Sedatives, Chloroarenes, Anticonvulsants, Ganaxolone, Antidepressant, Ketamine, Allosteric regulation

Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.

Key Points: 
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.
  • For more information visit www.marinuspharma.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210428006117/en/\n'

Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期一, 四月 12, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Anticonvulsants, GABAA receptor positive allosteric modulators, Ketones, Neurosteroids, Sterols, Chemical compounds, Ganaxolone, Chemistry

b'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cMarinus\xe2\x80\x9d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to Steven Pfanstiel, Marinus\xe2\x80\x99 newly-hired Chief Financial Officer and Treasurer.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cMarinus\xe2\x80\x9d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to Steven Pfanstiel, Marinus\xe2\x80\x99 newly-hired Chief Financial Officer and Treasurer.
  • The stock option was granted as an inducement material to Mr. Pfanstiel entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and is subject to the terms and conditions of the award agreement covering such grant.\nMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Marinus undertakes no obligation to update or revise any forward-looking statements.

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results

Retrieved on: 
星期二, 三月 9, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Biomedical Advanced Research and Development Authority, Life sciences, Companies, Health care, Ganaxolone, Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical and regulatory development activities and reported its financial results for the fourth quarter and fiscal year ended December 31, 2020.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical and regulatory development activities and reported its financial results for the fourth quarter and fiscal year ended December 31, 2020.
  • Although 2020 was extremely challenging for so many, we finished the year achieving several important milestones, which has provided momentum into 2021, said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals.
  • Marinus projects spend in the range of $18 to $20 million per quarter in 2021, offset by approximately $2 to $3 million per quarter from BARDA in 2021.
  • Marinus recognized $1.7 million in federal contract revenue in the year ended December 31, 2020 as a result of the BARDA contract the company entered into in September 2020.